Side effects of high-dose dobutamine are not prevented by normal saline infusion in dobutamine stress echocardiography

Tracy Hecker, Carmine G. De Pasquale, Rebecca Perry, Lynn Brown, Hari Koutsounis, Majo X. Joseph

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

High-dose dobutamine used in dobutamine stress echocardiography (DSE) has hemodynamically based side effects due to a variable combination of β1 (inotropic) and β2 (vasodilator) effects. Of concern is the development of an "empty ventricle syndrome" associated with intracavitary or outflow tract obstruction and resultant symptomatic hypotension. This study was undertaken to determine whether the concurrent administration of normal saline (N/S) would decrease symptoms, limit the development of left ventricular outflow tract (LVOT) obstruction and hypotension by maintaining left ventricular volume. One hundred patients, mean age 66 years ± 12, presenting for a DSE were randomized into two groups. One group (n = 50) received N/S at a rate of 800 ml/hour during the test, the second group received dobutamine alone. Patients were instructed to report and quantify symptoms on a scale of 1 to 10. Echocardiographic measurements of end systolic volume (ESV) and LVOT gradients were taken prior to dobutamine and at peak dose. There was no difference in symptom scores (3.5 ± 5.1(N/S) vs. 3.0 ± 4.7, P = 0.6), change in systolic blood pressure (BP) (-0.74 mmHg ± 33 (N/S) vs. -0.89 ± 35, P = 0.9) maximum LVOT gradient at peak (16.4 mmHg ± 16.1 (N/S) vs. 13.9 mmHg ± 9, P = 0.4), or ESV at peak (17.9 mL ± 13.4 (N/S) vs. 15.5 ml ± 10.6, P = 0.37). Furthermore, there was no difference in the number of patients (10/50 (20%) in both groups) who developed a significant LVOT gradient, defined as greater than 20 mmHg at peak dose. Despite the sound theoretical basis of N/S infusion to protect against "empty ventricle syndrome" during DSE this randomized trial does not demonstrate any symptomatic or hemodynamic benefit.

LanguageEnglish
Pages712-716
Number of pages5
JournalEchocardiography
Volume25
Issue number7
DOIs
Publication statusPublished - 1 Aug 2008
Externally publishedYes

Keywords

  • Dobutamine stress echocardiography
  • Hypotension
  • Saline

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Hecker, Tracy ; De Pasquale, Carmine G. ; Perry, Rebecca ; Brown, Lynn ; Koutsounis, Hari ; Joseph, Majo X. / Side effects of high-dose dobutamine are not prevented by normal saline infusion in dobutamine stress echocardiography. In: Echocardiography. 2008 ; Vol. 25, No. 7. pp. 712-716.
@article{81e22de944c5416f8b8df2451bc9365d,
title = "Side effects of high-dose dobutamine are not prevented by normal saline infusion in dobutamine stress echocardiography",
abstract = "High-dose dobutamine used in dobutamine stress echocardiography (DSE) has hemodynamically based side effects due to a variable combination of β1 (inotropic) and β2 (vasodilator) effects. Of concern is the development of an {"}empty ventricle syndrome{"} associated with intracavitary or outflow tract obstruction and resultant symptomatic hypotension. This study was undertaken to determine whether the concurrent administration of normal saline (N/S) would decrease symptoms, limit the development of left ventricular outflow tract (LVOT) obstruction and hypotension by maintaining left ventricular volume. One hundred patients, mean age 66 years ± 12, presenting for a DSE were randomized into two groups. One group (n = 50) received N/S at a rate of 800 ml/hour during the test, the second group received dobutamine alone. Patients were instructed to report and quantify symptoms on a scale of 1 to 10. Echocardiographic measurements of end systolic volume (ESV) and LVOT gradients were taken prior to dobutamine and at peak dose. There was no difference in symptom scores (3.5 ± 5.1(N/S) vs. 3.0 ± 4.7, P = 0.6), change in systolic blood pressure (BP) (-0.74 mmHg ± 33 (N/S) vs. -0.89 ± 35, P = 0.9) maximum LVOT gradient at peak (16.4 mmHg ± 16.1 (N/S) vs. 13.9 mmHg ± 9, P = 0.4), or ESV at peak (17.9 mL ± 13.4 (N/S) vs. 15.5 ml ± 10.6, P = 0.37). Furthermore, there was no difference in the number of patients (10/50 (20{\%}) in both groups) who developed a significant LVOT gradient, defined as greater than 20 mmHg at peak dose. Despite the sound theoretical basis of N/S infusion to protect against {"}empty ventricle syndrome{"} during DSE this randomized trial does not demonstrate any symptomatic or hemodynamic benefit.",
keywords = "Dobutamine stress echocardiography, Hypotension, Saline",
author = "Tracy Hecker and {De Pasquale}, {Carmine G.} and Rebecca Perry and Lynn Brown and Hari Koutsounis and Joseph, {Majo X.}",
year = "2008",
month = "8",
day = "1",
doi = "10.1111/j.1540-8175.2008.00688.x",
language = "English",
volume = "25",
pages = "712--716",
journal = "Echocardiography",
issn = "0742-2822",
publisher = "Wiley-Blackwell",
number = "7",

}

Side effects of high-dose dobutamine are not prevented by normal saline infusion in dobutamine stress echocardiography. / Hecker, Tracy; De Pasquale, Carmine G.; Perry, Rebecca; Brown, Lynn; Koutsounis, Hari; Joseph, Majo X.

In: Echocardiography, Vol. 25, No. 7, 01.08.2008, p. 712-716.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Side effects of high-dose dobutamine are not prevented by normal saline infusion in dobutamine stress echocardiography

AU - Hecker, Tracy

AU - De Pasquale, Carmine G.

AU - Perry, Rebecca

AU - Brown, Lynn

AU - Koutsounis, Hari

AU - Joseph, Majo X.

PY - 2008/8/1

Y1 - 2008/8/1

N2 - High-dose dobutamine used in dobutamine stress echocardiography (DSE) has hemodynamically based side effects due to a variable combination of β1 (inotropic) and β2 (vasodilator) effects. Of concern is the development of an "empty ventricle syndrome" associated with intracavitary or outflow tract obstruction and resultant symptomatic hypotension. This study was undertaken to determine whether the concurrent administration of normal saline (N/S) would decrease symptoms, limit the development of left ventricular outflow tract (LVOT) obstruction and hypotension by maintaining left ventricular volume. One hundred patients, mean age 66 years ± 12, presenting for a DSE were randomized into two groups. One group (n = 50) received N/S at a rate of 800 ml/hour during the test, the second group received dobutamine alone. Patients were instructed to report and quantify symptoms on a scale of 1 to 10. Echocardiographic measurements of end systolic volume (ESV) and LVOT gradients were taken prior to dobutamine and at peak dose. There was no difference in symptom scores (3.5 ± 5.1(N/S) vs. 3.0 ± 4.7, P = 0.6), change in systolic blood pressure (BP) (-0.74 mmHg ± 33 (N/S) vs. -0.89 ± 35, P = 0.9) maximum LVOT gradient at peak (16.4 mmHg ± 16.1 (N/S) vs. 13.9 mmHg ± 9, P = 0.4), or ESV at peak (17.9 mL ± 13.4 (N/S) vs. 15.5 ml ± 10.6, P = 0.37). Furthermore, there was no difference in the number of patients (10/50 (20%) in both groups) who developed a significant LVOT gradient, defined as greater than 20 mmHg at peak dose. Despite the sound theoretical basis of N/S infusion to protect against "empty ventricle syndrome" during DSE this randomized trial does not demonstrate any symptomatic or hemodynamic benefit.

AB - High-dose dobutamine used in dobutamine stress echocardiography (DSE) has hemodynamically based side effects due to a variable combination of β1 (inotropic) and β2 (vasodilator) effects. Of concern is the development of an "empty ventricle syndrome" associated with intracavitary or outflow tract obstruction and resultant symptomatic hypotension. This study was undertaken to determine whether the concurrent administration of normal saline (N/S) would decrease symptoms, limit the development of left ventricular outflow tract (LVOT) obstruction and hypotension by maintaining left ventricular volume. One hundred patients, mean age 66 years ± 12, presenting for a DSE were randomized into two groups. One group (n = 50) received N/S at a rate of 800 ml/hour during the test, the second group received dobutamine alone. Patients were instructed to report and quantify symptoms on a scale of 1 to 10. Echocardiographic measurements of end systolic volume (ESV) and LVOT gradients were taken prior to dobutamine and at peak dose. There was no difference in symptom scores (3.5 ± 5.1(N/S) vs. 3.0 ± 4.7, P = 0.6), change in systolic blood pressure (BP) (-0.74 mmHg ± 33 (N/S) vs. -0.89 ± 35, P = 0.9) maximum LVOT gradient at peak (16.4 mmHg ± 16.1 (N/S) vs. 13.9 mmHg ± 9, P = 0.4), or ESV at peak (17.9 mL ± 13.4 (N/S) vs. 15.5 ml ± 10.6, P = 0.37). Furthermore, there was no difference in the number of patients (10/50 (20%) in both groups) who developed a significant LVOT gradient, defined as greater than 20 mmHg at peak dose. Despite the sound theoretical basis of N/S infusion to protect against "empty ventricle syndrome" during DSE this randomized trial does not demonstrate any symptomatic or hemodynamic benefit.

KW - Dobutamine stress echocardiography

KW - Hypotension

KW - Saline

UR - http://www.scopus.com/inward/record.url?scp=48249148722&partnerID=8YFLogxK

U2 - 10.1111/j.1540-8175.2008.00688.x

DO - 10.1111/j.1540-8175.2008.00688.x

M3 - Article

VL - 25

SP - 712

EP - 716

JO - Echocardiography

T2 - Echocardiography

JF - Echocardiography

SN - 0742-2822

IS - 7

ER -